Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for SERA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 0.14M
March 31, 2026 0.02M
December 31, 2025 0.093M
September 30, 2025 0.373M
June 30, 2025 0.018M
March 31, 2025 53.54M
December 31, 2024 0.234M
September 30, 2024 0.117M
June 30, 2024 1.204M
March 31, 2024 1.054M
December 31, 2023 0.616M
September 30, 2023 0.128M
June 30, 2023 0.124M
Date Value
March 31, 2023 -0.116M
December 31, 2022 -0.116M
September 30, 2022 -0.008M
June 30, 2022 0.058M
March 31, 2022 0.071M
December 31, 2021 0.037M
September 30, 2021 68.92M
June 30, 2021 37.16M
March 31, 2021 53.47M
December 31, 2020 -0.92M
September 30, 2020 -0.938M
June 30, 2020 0.351M
March 31, 2020 10.67M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. 2.20M
BioRestorative Therapies, Inc. 4.441M
CareDx, Inc. -15.50M
Natera, Inc. 12.21M
Exagen, Inc. -0.37M